0001470831-25-000095.txt : 20250718 0001470831-25-000095.hdr.sgml : 20250718 20250718160109 ACCESSION NUMBER: 0001470831-25-000095 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250718 DATE AS OF CHANGE: 20250718 EFFECTIVENESS DATE: 20250718 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ikena Oncology, Inc. CENTRAL INDEX KEY: 0001835579 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-552269 FILM NUMBER: 251134446 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVE. CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-343-8292 MAIL ADDRESS: STREET 1: 50 NORTHERN AVE. CITY: BOSTON STATE: MA ZIP: 02210 D 1 primary_doc.xml X0708 D LIVE 0001835579 Ikena Oncology, Inc. 645 Summer Street, Suite 101 BOSTON MA MASSACHUSETTS 02210 857-273-8343 DELAWARE None None Corporation true Mark Manfredi 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Executive Officer Director Jotin Marango 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Executive Officer Jeffrey Ecsedy 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Executive Officer David Bonita 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Director Iain Dukes 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Director Jean-Francois Formela 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Director Otello Stampacchia 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Director Maria Koehler 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Director Richard Wooster 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Director Owen Hughes 645 Summer Street, Suite 101 Boston MA MASSACHUSETTS 02210 Director Biotechnology Decline to Disclose 06b false true false true true Concurrent private placement financing in connection with the Agreement and Plan of Merger made by and among the Issuer, Inmagene Biopharmaceuticals and certain other parties thereto, as described in the Form 8-K filed by the Issuer on December 23, 2024. 0 LEERINK PARTNERS LLC 39011 None None 53 STATE STREET, 40TH FLOOR BOSTON MA MASSACHUSETTS 02109 All States false 75000000 0 75000000 false 0 0 0 0 false Ikena Oncology, Inc. /s/ Jotin Marango Jotin Marango CFO, COO and Head of Corporate Development 2025-07-18